Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910557 · ClinicalTrials.gov registry record
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 187
- Enrollment target
NCT02910557 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 187 participants.
The verdict
NCT02910557 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 187 participants
- Enrollment target
Study Summary
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2026-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910557
The ClinicalTrials.gov registry entry for NCT02910557 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02910557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02910557 about?
NCT02910557 is a clinical study titled "Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection". A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in trea...
What is the current status of trial NCT02910557?
This trial is currently completed. The enrollment target is 187 participants. The study started on 2017-08-10. Estimated completion is 2026-01-30.
Who is sponsoring clinical trial NCT02910557?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.